Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Nat Biomed Eng. 2021 Aug 12;5(11):1348–1359. doi: 10.1038/s41551-021-00781-2

Extended data Fig. 1 |. Engineered Pmel-1 T cells enhance adoptive cell therapy in a high tumour burden setting.

Extended data Fig. 1 |

a, Schematic representation of large tumour B16-F10 bearing C57BL/6 J mice upon systemic T cell transfer. b, Tumour-growth curves following inoculation of B16F10 following transfer of engineered murine T cells on day 0 and heat treatments on days 1, 3, and 5 (*P = 0.0489 between untreated and cohorts which received cells only on day 8. *P = 0.0295 between cohorts receiving cells and heat versus cells only on day 12, **P = 0.0043 between cohorts receiving cells and heat versus cells only on day 14, two-way ANOVA and Tukey post-test and correction, mean ± SEM is depicted, n = 6–7 biologically independent mice).